Venture Life Group PLC

Latest Results (08.11.2025):

Venture Life Group PLC’s unaudited interim results for the period ended 30 June 2025 reveal a transformative quarter characterized by strong revenue growth, operational restructuring, and strategic divestments. During this period, the Group reported a 43.1% increase in revenue to £15.4 million, improved gross profit margins, and notable EBITDA growth, while also executing a major divestment of its CDMO and selective non-core products that generated €62 million in cash. These results underscore a shift towards a higher margin, brand-focused business model and a strengthened liquidity profile ahead of further strategic initiatives, including a planned share buyback programme.

Revenue & Profit Growth

Venture Life Group PLC achieved a significant revenue increase, up 43.1% to £15.4 million, with gross profit growing by 49.9% to £6.6 million. The improved gross margin of 43.1% reflects the positive impact of strategic marketing initiatives, even as marketing costs rose to 10.5% of revenue.

EBITDA & Operating Metrics

Adjusted EBITDA increased by 32.6% to £1.8 million, although the adjusted EBITDA margin declined to 11.6%. The operating loss widened to £1.4 million, while adjusted profit before tax improved to £0.8 million. Additionally, adjusted earnings per share improved to 0.83p compared to 0.26p in the previous year.

Strategic Divestment & Liquidity

The sale of the contract development and manufacturing operations and non-core product portfolio for €62 million has been a key strategic move. This divestment, coupled with the repayment of drawn funds against the revolving credit facility, has culminated in a strong net cash position of £34.1 million as of 30 September 2025.

Operational Developments & Future Plans

Operationally, the Group successfully integrated the acquisition of Health and Her Limited, which contributed £4.1 million in revenues and expanded distribution channels in the UK and US. Furthermore, new product launches and an anticipated share buyback programme targeting up to 12,805,231 ordinary shares highlight a dual focus on organic growth and strategic capital management.